MTOR and uveal melanoma: Moreover, the combination of MEK1/2 inhibitors with dual PI3K/MTOR inhibitors, or PKC inhibitors, enhanced uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner [35, 36].